Vyndamax
Print, digital and experintial design for Vyndamax, an oral prescription medication used to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. ATTR-CM is an underdiagnosed and potentially fatal disease of the heart muscle where a protein called transthyretin becomes misshapen and builds up in the heart, nerves and other organs. Vyndamax slows the progression of ATTR-CM by stabilizing the transthyretin protein, preventing it from misfolding and forming amyloid deposits in the heart.